Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.023 AUD | -4.17% | -4.17% | -34.29% |
May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
May. 16 | Chimeric Therapeutics Reopens Enrollment in Phase 1B Cell Therapy Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.29% | 13.73M | |
+8.20% | 115B | |
+12.81% | 107B | |
-13.55% | 22.31B | |
-4.16% | 21.6B | |
-6.00% | 18.23B | |
-39.93% | 17.62B | |
+7.33% | 14.26B | |
+33.41% | 12.37B | |
-27.23% | 8.28B |
- Stock Market
- Equities
- CHM Stock
- News Chimeric Therapeutics Limited
- Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20%